Viridian Therapeutics financials
$20.00−2.80%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $70.8M | $302.0K | $314.0K | $1.8M | $3.0M |
| Gross profit | $70.8M | $302.0K | $314.0K | $1.8M | $3.0M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$363.4M | -$299.0M | -$254.4M | -$134.3M | -$79.7M |
| Net income | -$281.9M | -$208.6M | -$175.0M | -$87.0M | -$79.4M |
| Net margin | −397.9% | −69059.6% | −55734.7% | −4912.1% | −2680.2% |
| Diluted EPS | $-3.32 | $-3.07 | $-3.91 | $-2.71 | $-6.66 |
| EBITDA | -$362.9M | -$298.5M | -$253.9M | -$134.0M | -$79.6M |
| Operating cash flow | -$276.4M | -$232.3M | -$184.2M | -$93.8M | -$54.6M |
| Free cash flow | -$276.9M | -$232.8M | -$185.1M | -$94.6M | -$54.9M |
| Diluted shares | 84.8M | 67.9M | 44.8M | 32.1M | 11.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $212.4M | $99.6M | $102.8M | $155.6M | $42.3M |
| Short-term investments | $662.3M | $618.0M | $374.5M | $269.0M | $154.7M |
| Total debt | $84.2M | $20.6M | $20.2M | $4.6M | $0.00 |
| Total assets | $899.4M | $742.4M | $490.4M | $435.1M | $203.7M |
| Total liabilities | $177.3M | $70.8M | $48.4M | $40.0M | $16.0M |
| Shareholders' equity | $722.2M | $671.6M | $442.0M | $395.1M | $187.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology